Jakafi 10 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DR26FDJC3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,365
Award facts
- Contract value 100% obligated
- $12,364.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,364.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of JAKAFI 10 mg tablets (60-count units). This firm fixed-price delivery order, issued on November 3, 2025, with an ultimate completion date of November 4, 2025, was awarded without set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to support recurring pharmaceutical and medical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal military medical supply chain, leveraging its small business status to compete effectively while maintaining consistent contract performance across multiple therapeutic categories. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with recent delivery orders ranging from under $100 to over $115,000. The PPV-G GEN V contract, awarded on November 13, 2025, carries a ceiling value of $499.999 billion with an ultimate completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting global military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FDJC3?
SPE2DR26FDJC3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DR26FDJC3 worth?
The government has obligated $12,365 on SPE2DR26FDJC3.
Is contract SPE2DR26FDJC3 an order under another contract?
Yes. SPE2DR26FDJC3 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJC3 competed?
The extent of competition for SPE2DR26FDJC3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award